Piper Sandler Raises ImmunityBio Target to $16 Following FDA Expansion

Key Facts

1Piper Sandler raised its price target for ImmunityBio from $12.00 to $16.00.

2The FDA expanded its approval for ANKTIVA to include patients with non-muscle-invasive bladder cancer.

3The new price target suggests an upside of approximately 61.5% from the current share price of $9.91.

Piper Sandler raised its price target for ImmunityBio from $12.00 to $16.00, according to Financial Modeling Prep. The revision follows the FDA's decision to expand its approval for the ANKTIVA therapy to include patients with non-muscle-invasive bladder cancer presenting with papillary-only tumors. The new target suggests a potential upside of approximately 61.5% from the current share price.

ImmunityBio (IBRX) closed at $9.91 on October 14, 2026, with a session range between a low of $9.35 and a high of $10.46. During the same period, Piper Sandler (PIPR) closed at $64.48 on October 14, 2026, after reaching an intraday high of $67.64.